The use of metaraminol as a vasopressor in critically unwell patients: a narrative review and a survey of UK practice

1Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: An evidence-based review. Crit Care Med. 2004;32(11 SUPPL.):455–65. Beale RJ Hollenberg SM Vincent JL Parrillo JE Vasopressor and inotropic support in septic shock: An evidence-based review Crit Care Med 200432 11 SUPPL 455 6510.1097/01.CCM.0000142909.86238.B115542956Search in Google Scholar

2ICNARC. Key statistics from the Case Mix Programme — adult , general critical care units Critical care units in the Case Mix Programme. Case Mix Program Summ Stat 2018 -19 [Internet]. 2019;(March 2019):1–11. Available from: htps://www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-Statistics Key statistics from the Case Mix Programme — adult , general critical care units Critical care units in the Case Mix Programme. Case Mix Program Summ Stat 2018 -19 [Internet] 2019(March 2019)1–11 Available from htps://www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-StatisticsSearch in Google Scholar

3NHS. Critical Care Minimum Dataset Full Specification [Internet]. 2010. Available from: htps://www.datadictionary.nhs.uk/data_sets/supporting_data_sets/critical_care_minimum_data_set.html Critical Care Minimum Dataset Full Specification [Internet] 2010 Available from htps://www.datadictionary.nhs.uk/data_sets/supporting_data_sets/critical_care_minimum_data_set.htmlSearch in Google Scholar

4Gamper G, Havel C, Arrich J, Losert H, Pace NL, Müllner M, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016 Feb 15;61(3):351–2. Gamper G Havel C Arrich J Losert H Pace NL Müllner M et al Vasopressors for hypotensive shock Cochrane Database Syst Rev. 2016 Feb 1561 3 351 210.1002/14651858.CD003709.pub4651685626878401Search in Google Scholar

5Holmesa CL, Walley KR. Vasoactive drugs for vasodilatory shock in ICU. Curr Opin Crit Care. 2009;15(5):398–402. Holmesa CL Walley KR Vasoactive drugs for vasodilatory shock in ICU Curr Opin Crit Care 200915 5 398 40210.1097/MCC.0b013e32832e96ef19542884Search in Google Scholar

6Laterre PF, Berry SM, Blemings A, Carlsen JE, François B, Graves T, et al. Effect of Selepressin vs Placebo on Ventilator-and Vasopressor-Free Days in Patients with Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;322(15):1476–85. Laterre PF Berry SM Blemings A Carlsen JE François B Graves T et al Effect of Selepressin vs Placebo on Ventilator-and Vasopressor-Free Days in Patients with Septic Shock: The SEPSIS-ACT Randomized Clinical Trial JAMA - J Am Med Assoc 2019322 15 1476 8510.1001/jama.2019.14607680226031577035Search in Google Scholar

7Guinot PG, Martin A, Berthoud V, Voizeux P, Bartamian L, Santangelo E, et al. Vasopressor-sparing strategies in patients with shock: A scoping-review and an evidence-based strategy proposition. J Clin Med. 2021;10(14). Guinot PG Martin A Berthoud V Voizeux P Bartamian L Santangelo E et al Vasopressor-sparing strategies in patients with shock: A scoping-review and an evidence-based strategy proposition J Clin Med 202110 1410.3390/jcm10143164830639634300330Search in Google Scholar

8Scheeren TWL, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC, et al. Current use of vasopressors in septic shock. Ann Intensive Care [Internet]. 2019;9(1):1–12. Scheeren TWL Bakker J De Backer D Annane D Asfar P Boerma EC et al Current use of vasopressors in septic shock Ann Intensive Care [Internet] 20199 1 1 1210.1186/s13613-019-0498-7635397730701448Search in Google Scholar

9Hamzaoui O, Scheeren TWL, Teboul JL. Norepinephrine in septic shock: When and how much? Curr Opin Crit Care. 2017;23(4):342–7. Hamzaoui O Scheeren TWL Teboul JL Norepinephrine in septic shock: When and how much? Curr Opin Crit Care 201723 4 342 710.1097/MCC.000000000000041828509668Search in Google Scholar

10Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine. 2017;45:486–552. Rhodes A Evans LE Alhazzani W Levy MM Antonelli M Ferrer R et al Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Critical Care Medicine 201745486 55210.1007/s00134-017-4683-628101605Search in Google Scholar

11Møller MH, Claudius C, Juntila E, Haney M, Oscarsson-Tibblin A, Haavind A, et al. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure. Acta Anaesthesiol Scand. 2016;60(10):1347– 66. Møller MH Claudius C Juntila E Haney M Oscarsson-Tibblin A Haavind A et al Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure Acta Anaesthesiol Scand 201660 10 1347–6610.1111/aas.12780521373827576362Search in Google Scholar

12Oba Y, Lone NA. Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials. J Crit Care. 2014;29(5):706–10. Oba Y Lone NA Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials J Crit Care 201429 5 706 1010.1016/j.jcrc.2014.04.01124857641Search in Google Scholar

13Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, et al. Efect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients with Vasodilatory Hypotension: A Randomized Clinical Trial. JAMA -J Am Med Assoc. 2020;323(10):938–49. Lamontagne F Richards-Belle A Thomas K Harrison DA Sadique MZ Grieve RD et al Efect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients with Vasodilatory Hypotension: A Randomized Clinical Trial JAMA -J Am Med Assoc 2020323 10 938 4910.1001/jama.2020.0930706488032049269Search in Google Scholar

14BNF. NOREPINEPHRINE | Drug | BNF content published by NICE [Internet]. [cited 2022 Mar 19]. Available from: htps://bnf.nice.org.uk/drug/noradrenalinenorepinephrine.html NOREPINEPHRINE | Drug | BNF content published by NICE [Internet] [cited 2022 Mar 19]. Available from htps://bnf.nice.org.uk/drug/noradrenalinenorepinephrine.htmlSearch in Google Scholar

15BNF. METARAMINOL | Drug | BNF content published by NICE [Internet]. [cited 2022 Mar 19]. Available from: htps://bnf.nice.org.uk/drug/metaraminol.html METARAMINOL | Drug | BNF content published by NICE [Internet] [cited 2022 Mar 19]. Available from htps://bnf.nice.org.uk/drug/metaraminol.htmlSearch in Google Scholar

16SHPA. Australian Injectable Drugs Handbook, 8th edition [Internet]. 2022 [cited 2022 Mar 19]. Available from: htps://aidh.hcn.com.au/login SHPA. Australian Injectable Drugs Handbook, 8th edition [Internet] 2022 [cited 2022 Mar 19]. Available from htps://aidh.hcn.com.au/loginSearch in Google Scholar

17Kelly FE, Fong K, Hirsch N, Nolan JP. Intensive care medicine is 60 years old: The history and future of the intensive care unit. Clin Med J R Coll Physicians London. 2014;14(4):376–9. Kelly FE Fong K Hirsch N Nolan JP Intensive care medicine is 60 years old: The history and future of the intensive care unit Clin Med J R Coll Physicians London 201414 4 376 910.7861/clinmedicine.14-4-376495283025099838Search in Google Scholar

18Vincent JL. Critical care--where have we been and where are we going? Crit Care. 2013;17 Suppl 1(Suppl 1):1–6. Vincent JL Critical care--where have we been and where are we going? Crit Care 2013 17 Suppl 1 Suppl 1 1 610.1186/cc11500360347923514264Search in Google Scholar

19PRISMA. PRISMA Protocols [Internet]. 2015. Available from: htp://prisma-statement.org/Protocols/ PRISMA. PRISMA Protocols [Internet] 2015 Available from htp://prisma-statement.org/Protocols/Search in Google Scholar

20Define - RX-Info [Internet]. Available from: htp://www.rx-info.co.uk/products/define.ashx Define - RX-Info [Internet] Available from htp://www.rx-info.co.uk/products/define.ashxSearch in Google Scholar

21Sardaneh AA, Penm J, Oliver M, Gatas D, McLachlan AJ, Patanwala AE. Pharmacoepidemiology of metaraminol in critically ill patients with shock in a tertiary care hospital. Aust Crit Care [Internet]. 2021;34(6):573–9. Sardaneh AA Penm J Oliver M Gatas D McLachlan AJ Patanwala AE Pharmacoepidemiology of metaraminol in critically ill patients with shock in a tertiary care hospital Aust Crit Care [Internet] 202134 6 573 910.1016/j.aucc.2021.01.00233663948Search in Google Scholar

22Da Silva PS, Furtado P. Methylene Blue to Treat Refractory Latex-Induced Anaphylactic Shock. A A Pract. 2018;10(3):57–60. Da Silva PS Furtado P Methylene Blue to Treat Refractory Latex-Induced Anaphylactic Shock A A Pract 201810 3 57 6010.1213/XAA.000000000000063028937421Search in Google Scholar

23Abu Sardaneh A, Penm J, Oliver M, Gattas D, Mclachlan A, Patanwala A. Comparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients. Eur J Hosp Pharm [Internet]. 2021 Oct 7;ejhpharm-2021-003035. Abu Sardaneh A Penm J Oliver M Gattas D Mclachlan A Patanwala A Comparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients Eur J Hosp Pharm [Internet] 2021 Oct 7;ejhpharm-2021-00303510.1136/ejhpharm-2021-00303534620686Search in Google Scholar

24Hou LC, Li SZ, Xiong LZ, Chen SY, Chen M, Zhang XJ, et al. Efect of dopamine and metaraminol on the renal function of patients with septic shock. Chin Med J (Engl). 2007;120(8):680–3. Hou LC Li SZ Xiong LZ Chen SY Chen M Zhang XJ et al Efect of dopamine and metaraminol on the renal function of patients with septic shock Chin Med J (Engl) 2007120 8 680 310.1097/00029330-200704020-00013Search in Google Scholar

25Anderson AK, Chatha H. Best evidence topic reports sepsis resulting in persistent hypotension Search outcomes BET 3 : Peripheral metaraminol infusion in the emergency department contained no relevant evidence or guide. Best evidence topic reports. 2017;34(3). Anderson AK Chatha H Best evidence topic reports sepsis resulting in persistent hypotension Search outcomes BET 3 : Peripheral metaraminol infusion in the emergency department contained no relevant evidence or guide Best evidence topic reports 201734 310.1136/emermed-2017-206590.3550223528232631Search in Google Scholar

26Hayward MD, Regan L, Glasheen J, Burns B. Review of therapeutic agents employed by an Australian aeromedical prehospital and retrieval service. EMA - Emerg Med Australas. 2016;28(3):329–34. Hayward MD Regan L Glasheen J Burns B Review of therapeutic agents employed by an Australian aeromedical prehospital and retrieval service EMA - Emerg Med Australas 201628 3 329 3410.1111/1742-6723.1258427250671Search in Google Scholar

27Redmond M, Knapp C, Salim M, Shanbhag S, Jaumdally R. Use of vasopressors in Takotsubo cardiomyopathy: A cautionary tale. Br J Anaesth. 2013;110(3):487–8. Redmond M Knapp C Salim M Shanbhag S Jaumdally R Use of vasopressors in Takotsubo cardiomyopathy: A cautionary tale Br J Anaesth 2013110 3 487 810.1093/bja/aes58623404978Search in Google Scholar

28Isbister GK, Duffull SB. Quetiapine overdose: Predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol. 2009;24(4):174–80. Isbister GK Duffull SB Quetiapine overdose: Predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal Int Clin Psychopharmacol 200924 4 174 8010.1097/YIC.0b013e32832bb07819494786Search in Google Scholar

29Dewachter P, Mouton-Faivre C, Emala CW, Riou B. Anaphylaxis and Anesthesia. Anesthesiology. 2009 Nov 1;111(5):1141–50. Dewachter P Mouton-Faivre C Emala CW Riou B Anaphylaxis and Anesthesia Anesthesiology 2009 Nov 1111 5 1141 5010.1097/ALN.0b013e3181bbd44319858877Search in Google Scholar

30Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol. 2005 Aug;5(4):359–64. Brown SG Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis Curr Opin Allergy Clin Immunol 2005 Aug; 5 4 359 6410.1097/01.all.0000174158.78626.3515985820Search in Google Scholar

31Wood DM, Wright KD, Jones AL, Dargan PI. Metaraminol (Aramine®) in the management of a significant amlodipine overdose. Hum Exp Toxicol. 2005;24(7):377–81. Wood DM Wright KD Jones AL Dargan PI Metaraminol (Aramine®) in the management of a significant amlodipine overdose Hum Exp Toxicol 200524 7 377 8110.1191/0960327105ht538oa16119252Search in Google Scholar

32Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care. 2005;11(5):413–7. Holmes CL Vasoactive drugs in the intensive care unit Curr Opin Crit Care 200511 5 413 710.1097/01.ccx.0000176696.70013.da16175026Search in Google Scholar

33Ruchti VEW, Wibrow BA, Seet J, Jacques A, Jha N, Anstey MH. A prospective comparison of peripheral metaraminol versus dilute noradrenaline in the intensive care unit. Anaesth Intensive Care. 2021;49(2):144–6. Ruchti VEW Wibrow BA Seet J Jacques A Jha N Anstey MH A prospective comparison of peripheral metaraminol versus dilute noradrenaline in the intensive care unit Anaesth Intensive Care 202149 2 144 610.1177/0310057X2098479433853391Search in Google Scholar

34Abu Sardaneh A, Goradia S, Narayan SW, Penm J, McLachlan AJ, Patanwala AE. Dose equivalence between metaraminol and norepinephrine in critical care. Br J Clin Pharmacol. 2021;(May):1–8. Abu Sardaneh A Goradia S Narayan SW Penm J McLachlan AJ Patanwala AE Dose equivalence between metaraminol and norepinephrine in critical care Br J Clin Pharmacol 2021 1–810.1111/bcp.1496934197654Search in Google Scholar

35Natalini G, Schivalocchi V, Rosano A, Taranto M, Pletti C, Bernardini A. Norepinephrine and metaraminol in septic shock: A comparison of the hemodynamic effects. Intensive Care Med. 2005;31(5):634–7. Natalini G Schivalocchi V Rosano A Taranto M Pletti C Bernardini A Norepinephrine and metaraminol in septic shock: A comparison of the hemodynamic effects Intensive Care Med 200531 5 634 710.1007/s00134-005-2607-315803299Search in Google Scholar

36Weiniger CF, Firman S. Drugs in Anaesthesia and Intensive Care, 5th Ed. Anesth Analg. 2017;124(2):691. Weiniger CF Firman S Drugs in Anaesthesia and Intensive Care, 5th Ed Anesth Analg 2017124 2 69110.1213/ANE.0000000000001752Search in Google Scholar

37De Backer D. Detailing the cardiovascular profile in shock patients. Crit Care. 2017;21(Suppl 3):311. De Backer D Detailing the cardiovascular profile in shock patients Crit Care 201721 Suppl 3 31110.1186/s13054-017-1908-6575163729297372Search in Google Scholar

38Bonanno FG. Physiopathology of shock. J Emergencies, Trauma Shock. 2011;4(2):222–32. Bonanno FG Physiopathology of shock J Emergencies, Trauma Shock 20114 2 222 3210.4103/0974-2700.82210313236321769210Search in Google Scholar

39Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA - J Am Med Assoc. 2017;317(14):1433–42. Vail E Gershengorn HB Hua M Walkey AJ Rubenfeld G Wunsch H Association between US norepinephrine shortage and mortality among patients with septic shock JAMA - J Am Med Assoc 2017317 14 1433 4210.1001/jama.2017.284128322415Search in Google Scholar